Asia-Pacific Cancer Vaccine Market – Segmented by type, technology, end-user and geography (2015-2020)

Published by: | Published Date: January, 2016 | Number of pages: NA


1. Executive Summary

2. Research Methodology

3. Introduction

3.1 Report Description

3.2 Markets Covered

4. Market Overview

4.1 Market Definition

4.2 Market Drivers

4.2.1 Increased Prevalence of Cancers

4.2.2 Rising Government and Non-Government Funding for Vaccine Development

4.2.3 Increasing Investments By Companies

4.2.4 Technological Advancements

4.3 Market Restraints

4.3.1 Cold Chain Management

4.3.2 Huge Capital Investments

4.3.3 Stringent Regulatory Procedures

4.4 Market Opportunitites

4.5 Market Threats

5. Porters Five Force Analysis

5.1 Bargaining Power of suppliers

5.2 Bargaining power of buyers

5.3 Degree of competition

5.4 Threat of substitution

5.5 Threat of new entrants

6. Market Segmentation

6.1 By Technology

6.1.1 Subunit Vaccines

6.1.2 Live Attenuated Vaccines

6.1.3 Conjugate Vaccines

6.1.4 Inactivated Vaccines

6.1.5 Recombinant Vector Vaccines

6.1.6 Toxoid Vaccines

6.1.7 Synthetic Vaccines

6.1.8 Dendritic Cell Vaccines

6.2 By Type

6.2.1 Preventive Vaccines

6.2.2 Therapeutic Vaccines

6.3 By Disease Indication

6.3.1 Cervical cancer

6.3.2 Others

6.4 By End User

6.4.1 Pediatrics

6.4.2 Adults

6.5 By Geography

6.5.1 China

6.5.2 India

6.5.3 Japan

6.5.4 Australia

6.5.5 Singapore

7. Competitive Landscape

7.1 Mergers & Acquisitions

7.2 Agreements, Collaborations & Partnerships

7.3 New Product Launches

7.4 Recommendations to new market players

7.5 Value Chain Analysis

8. Company Profiles

8.1 AstraZeneca plc

8.2 Aduro BioTech

8.3 Cytos

8.4 Galena Biopharma

8.5 Juvaris Biotherapeutics

8.6 MedImmune

8.7 Oxford BioMedica

8.8 Prima BioMed

8.9 GlaxoSmithKline

8.10 Sanofi

8.11 Merk&co

8.12 Ubivac

8.13 Vaccinogen

9. Appendix

9.1 Abbrevations

9.2 Sources

9.3 Bibliography

9.4 Disclaimer
Request Data
Request Data
Request Data
Cancer vaccines are biological preparations that stimulate or strengthen a person's immune system against cancer. Cancer vaccines are usually administered intravenously. They can be used for both adults and children. The vaccines can be broadly classified into prophylactic and therapeutic vaccines. Prophylactic vaccines are used for the prevention of cancer, whereas therapeutic vaccines are used for treatment of the disease. Mordor Intelligence analysts forecast the Asia-Pacific cancer vaccines market to grow at a CAGR of 12-20% over the period 2015-2020. The Asia-Pacific market is currently estimated to be valued at USD 209 million as per 2015.

The market for cancer vaccines is much smaller than other cancer therapeutic categories. The size of the market can be attributed to the nascent stages of industry life cycle and the late introduction of the vaccines in the market. To tap this market, many companies from Asia-Pacific are actively investing in cancer vaccine development. The market penetration is expected to increase with the increase in competition among the various pharmaceutical companies to obtain a larger portion of this market.

The Asia-Pacific cancer vaccines market is segmented based on:

Subunit Vaccines
Live Attenuated Vaccines
Conjugate Vaccines
Inactivated Vaccines
Recombinant Vector Vaccines
Toxoid Vaccines
Synthetic Vaccines
Dendritic Cell Vaccines
Preventive Vaccines
Therapeutic Vaccines
Disease Indication
Cervical cancer
End user
According to the World Health Organization, 14-million incidences of cancer and 8.2-million cancer deaths were recorded in 2012. Lung, prostate, colorectal, cervical, and breast cancers remain the most common forms of cancer. Thus, there is a rise in demand for vaccines to prevent and treat cancers.

Asia is poised to grow at the highest CAGR during the forecast period, owing to governmental initiatives, rising focus of major players on the Indian vaccine technology market, and increasing immunization initiatives by organizations such as World Health Organization and GAVI in these regions.

Some of the key participants in the industry include Prima BioMed, GlaxoSmithKline, Sanofi S.A, Merck, Aduro BioTech, AstraZeneca plc, OXFORD BIOMEDICA etc.


Increasing cancer cases
Technological developments
Drug innovations with regard to the cancer
Government initiatives
Rise in aging populace
Advanced health care services
Upsurge in awareness about cancer and their available therapies in the market
Increasing health care expenditure

Cold chain, or temperature-controlled supply chain, management
Low accessibility to vaccines in remote areas
Stringent regulatory procedures